6 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARa Selective Agonist.
Bristol-Myers Squibb Co.
Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR)ß Agonist.
Vitae Pharmaceuticals Inc
Discovery of Second Generation ROR? Inhibitors Composed of an Azole Scaffold.
Kyoto Prefectural University of Medicine
Modeling, Synthesis, and Biological Evaluation of Potential Retinoid X Receptor (RXR)-Selective Agonists: Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(5,5,8,8-tetrahydronaphthalen-2-yl)amino)nicotinic Acid (NEt-TMN).
Arizona State University
Discovery of potent and selective PPAR?/? dual antagonists and initial biological studies.
Structure-activity relationship study on benzoic acid part of diphenylamine-based retinoids.
Tohoku Pharmaceutical University